Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dedov, I.
Right arrow Articles by Palazzini, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dedov, I.
Right arrow Articles by Palazzini, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 12, Issue 11 2295-2300, Copyright © 1997 by Oxford University Press

ORIGINAL ARTICLES

A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy

I Dedov, M Shestakova, A Vorontzov and E Palazzini
National Research Centre for Endocrinology, Moscow, Russia; Corresponding author at: Medical Department, Alfa Wassermann SpA, Via Ragazzi del '99, 5, I-40133 Bologna, Italy

Background: Glycosaminoglycans (GAGs) play an important role in the physiopathology of diabetic nephropathy; they are essential for the maintenance of glomerular charge selectivity and their administration can reduce albuminuria in diabetic patients. Methods: Following a randomized block design, controlled versus placebo, we investigated, in insulin-dependent diabetic patients with micro- or macroalbuminuria, whether GAG therapy can influence an altered albumin excretion rate (AFR). Thirty-six patients (18 micro- and 18 macroalbuminuric) were randomized to receive, during 5 days/week for 3 weeks, either a daily dose of 700 lipoproteinlipase releasing units (LRU) of sulodexide by the i.m. route (9 micro- and 9 macroalbuminuric patients), or a matching i.m. placebo (or micro- and 9 macroalbuminuric patients). All patients were followed-up for further 6 weeks. AER was evaluated before treatment, weekly during it and every 3 weeks during follow-up. Results: Seventeen of the 18 sulodexide-treated patients showed a trend towards decrease in AER, more evident and statistically significant in microalbuminurics (P <0.01 after the first week). At the end of follow-up, AER was still significantly reduced in microalbuminurics, while macroalbuminurics showed again increased values. Placebo-treated patients evidenced no AER variations during all the study period. No statistically significant differences vs baseline, concerning blood pressure, haematological, haematochemical and coagulative tests, and urinalysis, were ever observed, apart from a clear-cut decrease in blood cholesterol and triglycerides at the end of treatment, in a subgroup of hyperlipidaemic, sulodexide-treated subjects. No adverse events were registered. Conclusions: Our results suggest that the GAG sulodexide exerts a positive activity in type I diabetic patients with micro- and macroalbuminuria, by reducing the abnormally high AER levels. Key words: albuminuria; diabetes mellitus; diabetic nephropathy; glycosaminoglycans
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
H. L. Heerspink, T. Greene, J. B. Lewis, I. Raz, R. D. Rohde, L. G. Hunsicker, S. L. Schwartz, S. Aronoff, M. A. Katz, G. M. Eisner, et al.
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1946 - 1954.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. J. Lewis and X. Xu
Abnormal Glomerular Permeability Characteristics in Diabetic Nephropathy: Implications for the therapeutic use of low-molecular weight heparin
Diabetes Care, February 1, 2008; 31(Supplement_2): S202 - S207.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
B. M. Errichi, M. R. Cesarone, G. Belcaro, R. Marinucci, A. Ricci, A. Ippolito, R. Brandolini, G. Vinciguerra, M. Dugall, A. Felicita, et al.
Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry
Angiology, May 1, 2004; 55(3): 243 - 249.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Gambaro, I. Kinalska, A. Oksa, P. Pont'uch, M. Hertlova, J. Olsovsky, J. Manitius, D. Fedele, S. Czekalski, J. Perusicova, et al.
Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients: The Di.N.A.S. Randomized Trial
J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1615 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. GAMBARO and F. J. VAN DER WOUDE
Glycosaminoglycans: Use in Treatment of DiabeticNephropathy
J. Am. Soc. Nephrol., February 1, 2000; 11(2): 359 - 368.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. W. VAN DER PIJL, H. H. P. J. LEMKES, M. FRÖLICH, F. J. VAN DER WOUDE, F. J. M. VAN DER MEER, and L. A. VAN ES
Effect of Danaparoid Sodium on Proteinuria, von Willebrand Factor, and Hard Exudates in Patients with Diabetes Mellitus Type 2
J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1331 - 1336.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.